Estimated impact of fezolinetant versus placebo on work productivity and indirect costs among women experiencing vasomotor symptoms associated with menopause

Fezolinetant demonstrated improvements in work productivity and reduced estimated indirect costs versus placebo for women with moderate to severe VMS, including HT-unsuitable women who often face limited treatment options, maintained through 52 weeks.